You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 16, 2024

LURBINECTEDIN - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for lurbinectedin and what is the scope of patent protection?

Lurbinectedin is the generic ingredient in one branded drug marketed by Jazz and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Lurbinectedin has thirty-two patent family members in twenty-three countries.

One supplier is listed for this compound.

Summary for LURBINECTEDIN

International Patents:	32
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	32
Clinical Trials:	34
Patent Applications:	184
What excipients (inactive ingredients) are in LURBINECTEDIN?	LURBINECTEDIN excipients list
DailyMed Link:	LURBINECTEDIN at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LURBINECTEDIN

Generic Entry Date for LURBINECTEDIN^: ⤷ Try a Trial* Constraining patent/regulatory exclusivity: ⤷ Try a Trial Dosage: POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LURBINECTEDIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ERLINDA M GORDON	Phase 1/Phase 2
Amgen	Phase 3
M.D. Anderson Cancer Center	Phase 1

See all LURBINECTEDIN clinical trials

Pharmacology for LURBINECTEDIN

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

US Patents and Regulatory Information for LURBINECTEDIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for LURBINECTEDIN

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Hungary	0401174		⤷ Try a Trial
Japan	4684552		⤷ Try a Trial
Poland	367940		⤷ Try a Trial
Portugal	1414828		⤷ Try a Trial
Mexico	PA04001240	ANALOGOS ANTITUMORALES. (ANTITUMORAL ANALOGS.)	⤷ Try a Trial
Russian Federation	2283842	ПРОИЗВОДНЫЕ ЭКТЕИНАСЦИДИНА, ИХ ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ECTEINASCIDIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION)	⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for LURBINECTEDIN

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LURBINECTEDIN

Recent Clinical Trials for LURBINECTEDIN

Pharmacology for LURBINECTEDIN

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LURBINECTEDIN